Guidelines of the French Society of Otorhinolaryngology (SFORL) : Nonsteroidal anti-inflammatory drugs (NSAIDs) and pediatric ENT infections. Short version
Copyright © 2019 Elsevier Masson SAS. All rights reserved..
OBJECTIVES: To present the guidelines of the French Society of Otolaryngology-Head and Neck Surgery concerning the use of non-steroidal anti-inflammatory drugs (NSAIDs) in pediatric ENT infections.
METHODS: Based on a critical analysis of the medical literature up to November 2016, a multidisciplinary workgroup of 11 practitioners wrote clinical practice guidelines. Levels of evidence were classified according to the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) system: GRADE A, B, C or "expert opinion". The first version of the text was reworked by the workgroup following comments by the 22 members of the reading group.
RESULTS: The main recommendations are: NSAIDs are indicated at analgesic doses (e.g. 20-30 mg/kg/day for ibuprofen) in combination with paracetamol (acetaminophen) in uncomplicated pediatric ENT infections (acute otitis media, tonsillitis, upper respiratory infections, and maxillary sinusitis) if: o pain is of medium intensity (visual analogue scale (VAS) score 3-5 or "Evaluation Enfant Douleur" (EVENDOL) child pain score 4-7) and insufficiently relieved by first-line paracetamol (residual VAS≥3 or EVENDOL≥4); o pain is moderate to intense (VAS 5-7 or EVENDOL 7-10). When combined, paracetamol and ibuprofen are ideally taken simultaneously every 6h. It is recommended: (1) o not to prescribe NSAIDs in severe or complicated pediatric ENT infections; (2) o to suspend NSAIDs treatment in case of unusual clinical presentation of the infection (duration or symptoms); (3) o not to prescribe NSAIDs for more than 72h.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:136 |
|---|---|
| Enthalten in: |
European annals of otorhinolaryngology, head and neck diseases - 136(2019), 4 vom: 19. Sept., Seite 289-294 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Truffert, E [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.03.2020 Date Revised 09.03.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.anorl.2019.04.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM300304846 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM300304846 | ||
| 003 | DE-627 | ||
| 005 | 20231225102224.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.anorl.2019.04.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1000.xml |
| 035 | |a (DE-627)NLM300304846 | ||
| 035 | |a (NLM)31420238 | ||
| 035 | |a (PII)S1879-7296(19)30061-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Truffert, E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Guidelines of the French Society of Otorhinolaryngology (SFORL) |b Nonsteroidal anti-inflammatory drugs (NSAIDs) and pediatric ENT infections. Short version |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.03.2020 | ||
| 500 | |a Date Revised 09.03.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a OBJECTIVES: To present the guidelines of the French Society of Otolaryngology-Head and Neck Surgery concerning the use of non-steroidal anti-inflammatory drugs (NSAIDs) in pediatric ENT infections | ||
| 520 | |a METHODS: Based on a critical analysis of the medical literature up to November 2016, a multidisciplinary workgroup of 11 practitioners wrote clinical practice guidelines. Levels of evidence were classified according to the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) system: GRADE A, B, C or "expert opinion". The first version of the text was reworked by the workgroup following comments by the 22 members of the reading group | ||
| 520 | |a RESULTS: The main recommendations are: NSAIDs are indicated at analgesic doses (e.g. 20-30 mg/kg/day for ibuprofen) in combination with paracetamol (acetaminophen) in uncomplicated pediatric ENT infections (acute otitis media, tonsillitis, upper respiratory infections, and maxillary sinusitis) if: o pain is of medium intensity (visual analogue scale (VAS) score 3-5 or "Evaluation Enfant Douleur" (EVENDOL) child pain score 4-7) and insufficiently relieved by first-line paracetamol (residual VAS≥3 or EVENDOL≥4); o pain is moderate to intense (VAS 5-7 or EVENDOL 7-10). When combined, paracetamol and ibuprofen are ideally taken simultaneously every 6h. It is recommended: (1) o not to prescribe NSAIDs in severe or complicated pediatric ENT infections; (2) o to suspend NSAIDs treatment in case of unusual clinical presentation of the infection (duration or symptoms); (3) o not to prescribe NSAIDs for more than 72h | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Abscess | |
| 650 | 4 | |a Acute otitis media | |
| 650 | 4 | |a Analgesic | |
| 650 | 4 | |a Maxillary sinusitis otitis | |
| 650 | 4 | |a NSAIDs | |
| 650 | 4 | |a Nonsteroidal anti-inflammatory drugs | |
| 650 | 4 | |a Pain | |
| 650 | 4 | |a Pediatric ENT infections | |
| 650 | 4 | |a Pharyngitis | |
| 650 | 4 | |a Tonsillitis | |
| 650 | 7 | |a Analgesics, Non-Narcotic |2 NLM | |
| 650 | 7 | |a Anti-Inflammatory Agents, Non-Steroidal |2 NLM | |
| 650 | 7 | |a Acetaminophen |2 NLM | |
| 650 | 7 | |a 362O9ITL9D |2 NLM | |
| 700 | 1 | |a Fournier Charrière, E |e verfasserin |4 aut | |
| 700 | 1 | |a Treluyer, J-M |e verfasserin |4 aut | |
| 700 | 1 | |a Blanchet, C |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, R |e verfasserin |4 aut | |
| 700 | 1 | |a Gardini, B |e verfasserin |4 aut | |
| 700 | 1 | |a Haas, H |e verfasserin |4 aut | |
| 700 | 1 | |a Liard, F |e verfasserin |4 aut | |
| 700 | 1 | |a Montastruc, J-L |e verfasserin |4 aut | |
| 700 | 1 | |a Nicollas, R |e verfasserin |4 aut | |
| 700 | 1 | |a Pondaven, S |e verfasserin |4 aut | |
| 700 | 1 | |a Stahl, J-P |e verfasserin |4 aut | |
| 700 | 1 | |a Wood, C |e verfasserin |4 aut | |
| 700 | 1 | |a Couloigner, V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European annals of otorhinolaryngology, head and neck diseases |d 2010 |g 136(2019), 4 vom: 19. Sept., Seite 289-294 |w (DE-627)NLM201398648 |x 1879-730X |7 nnns |
| 773 | 1 | 8 | |g volume:136 |g year:2019 |g number:4 |g day:19 |g month:09 |g pages:289-294 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.anorl.2019.04.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 136 |j 2019 |e 4 |b 19 |c 09 |h 289-294 | ||